GLP-1 Effectiveness, Mechanisms of Action and Potential Part 4 of 4.

Slides:

Advertisements

Similar presentations

GLP-1 (7-36 & 9-36) ELISA ‘Total Amide’ ‘Active’.

Advertisements

Cardiovascular II.

Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:

Involvement of the Mitochondrial Calcium Uniporter in Cardioprotection by Ischemic Preconditioning.

DPP4-Inhibition and Coronary Artery Disease Mary Anne Lim-Abrahan, MD, FPCP, FPSEM Professor, Endocrinology, Diabetes & Metabolism Dept. of Medicine, UP.

20 Cardiovascular Disease and Physical Activity chapter.

Hyperglycemia at the Vessel Wall. Potential hyperglycemia-induced tissue damage Brownlee M. Diabetes. 2005;54: Repeated acute changes in cellular.

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 1.

Yan Wu, Xiangru Lu, Fuli Xiang, and Qingping Feng

Introduction to ROS in the Cardiovascular System John F. Keaney, Jr., M.D. UMass Medical School Worcester, MA.

Fig Summary of physiological function of the incretins GLP-1 and GIP on islet cells The Islets of Langerhans, Islam, Md. Shahidul (Ed.) ISBN: ,

Hyperglycemia and Acute Coronary Syndromes. Cardiovascular disease and diabetes Bell DSH. Diabetes Care. 2003;26: Centers for Disease Control.

Part 7. GLUT2 AMG Uptake NGTT2DMNGTT2DM AMG=methyl-  -D-[U 14 C]-glucopyranoside; CPM=counts per minute. Rahmoune H, et al. Diabetes. 2005;54:

Chapter 9: Circulatory Adaptations to Exercise

Regulation of Blood Sugar Level at the Whole Animal Owen M c Guinness January 11, 2010 Course: MPB 333 Contact info: Phone: Office: 831C Light.

Endothelial Progenitor Cells (EPCs)

Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 3.

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.

A Critical Analysis of the Clinical Use of Incretin-Based Therapies The benefits by far outweigh the potential risks Featured Article: Diabetes Care Volume.

Part 2 of 2.  GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular.

Vascular Effects of Insulin: Implications for Hyperglycemia Management.

 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.

Diabetes and Myocardial Ischaemia - Sensitivity of the diabetic heart to ischemic injury.

SGLT2 INHIBITION: A NOVEL TREATMENT STRATEGY FOR TYPE 2 DIABETES MELLITUS.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

The cardiac cycle Ventricular filling the diastole refers to the period of the cardiac cycle during which the ventricles are filling with blood the systole.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions?

Fig. 2. Neuroprotective effects of ex-4 through the G protein-coupled GLP-1 receptor. (A) Infarct volume was assessed by TTC staining after tMCAO in rats.

GLP-1 Modulates Numerous Functions in Humans

Percutaneous Carbon Dioxide Gas Mist Ameliorates Cardiac Remodeling

6.Fat- increased lipolysis, inc FFA

Normal And Abnormal Cardiac Muscle Metabolism

by Thomas H. Marwick, and Markus Schwaiger Circ Cardiovasc Imaging

GLP-1 Agonists and Cardiovascular Health

Prostaglandin E2 Protects the Heart From Ischemia-Reperfusion Injury via Its Receptor Subtype EP4 by Chun-Yang Xiao, Koh-ichi Yuhki, Akiyoshi Hara, Takayuki.

The percentage of subjects with de novo development of renal function impairment (GFR

Diastolic heart failure

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 3.

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Safia Costes, Peter C. Butler Cell Metabolism

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

The Cardiovascular Biology of Glucagon-like Peptide-1

Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.

cardiovascular and renal systems

MI during active phase (ZT13) leads to infarct expansion and reduced cardiac function MI during active phase (ZT13) leads to infarct expansion and reduced.

A New Drug Target for Type 2 Diabetes

DIABETES MELLITUS. DIABETES MELLITUS It is a syndrome of impaired carbohydrate, protein and fat metabolism caused by either lack of insulin secretion.

Volume 18, Issue 13, Pages (March 2017)

Figure 1 Sites of action of glucose-lowering agents

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

Dandan Wang et al. BTS 2018;3: Overexpression of miR-24 Ameliorates Diabetic Ischemia/Reperfusion Injury (A) Schematic protocol of miR-24 delivery.

CARDIOVASCULAR AGENTS

Volume 19, Issue 6, Pages (June 2014)

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

The Cardiovascular Biology of Glucagon-like Peptide-1

Volume 14, Issue 2, Pages (August 2011)

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 6.

Incretin Physiology in Type 2 Diabetes Mellitus

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Chronic rapamycin treatment impairs β-cell mass and insulin clearance in rats. Chronic rapamycin treatment impairs β-cell mass and insulin clearance in.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.

Cardioprotective effects of ivabradine administration in the setting of acute coronary syndromes and myocardial infarction. Cardioprotective effects of.

Presentation transcript:

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 4 of 4

Diabetes 53:2397;2004 Treatment with Exenatide does not impair the counterregulatory glucagon response

Incretin-related Anti-diabetes Drugs and effects on plasma glucagon Hyperglucagonemia contributes to abnormal glucose homeostasis in T2DM GLP-1r activation reduces fasting and postprandial glucagon concentrations Neither DPP-4 inhibition nor Ex-4 interferes with the glucagon response to hypoglycemia. GLP-1r activation may sensitize the alpha-cell to regulation by glucose.

Does activation of the GLP-1r improve cardiac function? A new extra-islet target for GLP-1: The Heart

The GLP-1r and the Heart 1.The GLP-1r is expressed in cardiomyocytes and in vascular endothelial cells. 2.Activation of the GLP-1r in cardiomyocytes in vitro increases cAMP levels and glucose uptake. 3.GLP-1r knock-out mice have increased ventricular thickness and increased end-diastolic pressure. 4.In rodents GLP-1 increases HR through a CNS pathway.

Expression of the GLP-1r in CV tissues CardiomyocytesEndocardiumEndothelium/SMC Anti-actin Anti-GLP-1r Nuclear stain K Ban, Circulation 2008

Effects of GLP-1r agonists on LVDP before and after ischemia/reperfusion K Ban, Circulation 2008 EquilibIschReperfEquilibIschReperf

Effects of GLP-1 peptides on coronary blood flow, ischemic LDH levels, and glucose uptake K Ban, Circulation 2008

Effects of IV GLP–1 on Cardiac Metabolism and Function in Experimental CHF Nikolaidis LA, et al. Circulation. 2004;110: P ≤ 0.05 P ≤ 0.01 P < P < Stroke Volume Ejection Fx Myocardial Glucose Uptake

GLP-1 decreases pyruvate and lactate in the ischemic & non-ischemic porcine myocardium Kavianipour, Peptides 2003

Effects of IV GLP–1 on Ventricular Function and Wall Motion Post-MI Ejection fraction Wall motion abnormality 1.5 – 2.0 – 2.5 – 3.0 – rGLP-1 Control Nikolaidis LA, et al. Circulation. 2004;109: LVEF (%) ASE-RWMSI (%) ASE-Regional Wall Motion Score (IZ–WMSI) ASE-Regional Wall Motion Score (IZ–WMSI) P < 0.01

Effect of GLP–1 on Infarct Size in Experimental Ischemia Bose AK, et al. Diabetes. 2005;54: Bose AK, et al. Diabetes. 2005;54: Infarct-to-risk ratio (%) * ControlVal-PyrrolGLP-1Exendin-(9-39)

Effect of GLP-1 on endothelial-dependent and independent Blood Flow in non-Diabetic humans A Basu, AJP 2007 Endothelial-Dependent Endothelial-Independent

E Mannucci, Nutr Metab Cardiovasc Dis, 2008

Summary 1.GLP-1 is essential for normal glucose tolerance and the GLP-1r system is useful for treating diabetes. 2.GLP-1 acts via multiple mechanisms to improve glucose tolerance. 3.The mechanism of action of GLP-1r agonists and DPP-4 inhibitors includes islet α- and β-cell effects 4.Effects of GLP-1r signaling on cardiovascular function are still under investigation but there is experimental evidence that this could be another beneficial component of pharmacology.